Physician profile
Kenneth R Smith
NPI 1942396023
$8,476.33
in general payments reported to CMS, 2019-2025
35 companies · $405 in 2025
The $405 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,067 · 2020: $649 · 2021: $3,152 · 2022: $1,131 · 2023: $953 · 2024: $1,120 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,478.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,380.63 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $1,130.78 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $841.19 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $752.10 | 2019-2025 | Mounjaro, Amyvid, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $706.76 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $704.67 | 2020-2025 | Ozempic, Rybelsus |
| Amgen INC. | $407.79 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbott Laboratories | $355.24 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $305.82 | 2019-2024 | |
| Glaxosmithkline, LLC. | $290.61 | 2019-2022 | |
| Boston Scientific Corporation | $203.44 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $190.85 | 2019-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $147.77 | 2019-2022 | |
| Allergan, INC. | $138.00 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $123.50 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $100.65 | 2020-2023 | Hetlioz |
| Merck Sharp & Dohme LLC | $87.12 | 2019-2024 | Belsomra, Capvaxive, Gardasil |
| Sanofi-Aventis U.S. LLC | $72.84 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $58.46 | 2021-2023 | |
| Sanofi Pasteur INC. | $58.40 | 2019-2023 | |
| Amarin Pharma, INC. | $56.85 | 2019-2022 | |
| Eisai INC. | $50.36 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $47.42 | 2022 | |
| Exact Sciences Corporation | $46.52 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $33.78 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $27.01 | 2020 | |
| Inspire Medical Systems, INC. | $22.39 | 2025 | Inspire |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.29 | 2023 | Lifevest |
| Xeris Pharmaceuticals, INC. | $20.03 | 2021 | |
| Shire North American Group INC | $19.22 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.15 | 2019 | |
| Celltrion USA INC. | $18.14 | 2024 | Vegzelma |
| Endo Pharmaceuticals INC. | $14.62 | 2019 | |
| Vistapharm, INC. | $12.60 | 2021 | |
| Genentech USA, INC. | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.